27
Participants
Start Date
April 13, 2020
Primary Completion Date
October 30, 2022
Study Completion Date
March 30, 2023
Anlotinib hydrochloride
Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
RECRUITING
Hangzhou Cancer Hospital, Hangzhou
Collaborators (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
First People's Hospital of Hangzhou
OTHER